Rep. Burgess Vows To Fight FDA Panel Conflict-Of-Interest Restrictions
This article was originally published in The Gray Sheet
Executive Summary
Relaxing conflict-of-interest restrictions for FDA advisory panels will be a top priority for Texas Republican Congressman Michael Burgess during the upcoming reauthorization of device and drug user fee programs, he said Sept. 26.
You may also be interested in...
Draft User Fee Bills Aim To Streamline And Strengthen Device Regs
Details on draft legislation circulating in the House and Senate.
Rep. Burgess Not Changing Conflict-Of-Interest Thinking Despite Advisory Committee Flap
Sponsor of bill that would loosen conflict of interest rules says requiring public release of financial disclosure documents, as one group suggested, may not require a legislative fix.
Flurries Of New Bills Advance Device Industry Interests In Congress
The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.